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Introduction: Approximately ten to fifteen percent of patients with myasthenia gravis are found to have a thymoma,
and twenty to twenty-five percent of patients with thymoma have myasthenia gravis. Thymomatous myasthenia gravis
tends to have a difficult clinical course and poor prognosis.
Case presentation: We report two cases (one patient of Asian ethnicity and the other of Caucasian ethnicity) of
atypical presentations of myasthenia gravis associated with invasive malignant thymoma. Both patients were
diagnosed at a young age, in their 20s. They presented with a turbulent course of myasthenia gravis and recurrent
thymoma, but obtained good outcome after aggressive treatment involving multiple different specialists.
Conclusions: Although thymomatous myasthenia gravis tends to have a difficult clinical course and poor prognosis,
early and aggressive treatment along with multidisciplinary management may improve the outcome of these patients.
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Although the relationship between myasthenia gravis (MG)
and thymoma is well documented, the prevalence and
characteristics of MG associated with invasive thymoma
are less known. Approximately ten to fifteen percent
of patients with MG are found to have a thymoma.
Conversely, in patients with thymoma, 40 percent
have an associated autoimmune condition, presumably
paraneoplastic in etiology. Twenty to twenty-five percent
of patients with thymoma have myasthenia gravis [1].
Thymoma-associated MG (T-MG) is identified as a
tumor originating from thymic epithelial cells, most
being cortical subtype (World Health Organization type
B) [2]. Because cortical thymoma usually has some mor-
phological similarities with the thymic cortex, they share
the ability to propagate the maturation of immature naive* Correspondence: rison@usc.edu
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iphery. The pathogenesis of T-MG suggests that epithelial
neoplastic cells encircled by maturing T cells are capable
of expressing epitopes cross-reactive with skeletal muscle
proteins, such as acetylcholine receptor (AChR) [3]. AChR
antibodies have been detected in all patients with T-MG.
The AChR antibody directly attacks the neuromuscular
junction, affecting the endplate region of the postsynaptic
membrane, specifically aimed at the nicotinic acetylcho-
line receptors [4].
The patient’s genetic profile may also play an important
role as well as the thymic ability to export autoreactive T
cells in developing MG. Research has shown that MG has
a genetic association to HLA-DR3 or ancestral haplotype
8.1 in early-onset MG. The thymoma patients with a
particular genetic profile convey high risk of developing
MG [5].
The incidence of thymoma in the United States is 0.15
per 100,000 person-years. Asians, Pacific Islanders and
African Americans appear more frequently among thym-
oma patients [6]. T-MG is equally common in men and
women and occurs at any age with a peak onset around
50 years [3]. Thymoma is a unique thymic epithelialal Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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local invasiveness and metastases [6].
Thymoma is graded according to the World Health
Organization (WHO) histological classification [7] and is
classified by the Masaoka staging system [8]. Above stage
II is considered to be invasive. The incidence of MG
associated with invasive high-stage malignant thymoma
is rare. The severity of the MG is evaluated according to
the Medical Scientific Advisory Board of the Myasthenia
Gravis Foundation of America clinical classification sys-
tem (MGFA), which was established in 2000 [9].
Thymomatous MG tends to have a difficult clinical
course and poor prognosis [10]. We report here two cases
of atypical presentations of MG associated with invasive
malignant thymoma. Both patients were diagnosed at a
young age, in their 20s. They presented with a turbulent
course of MG and recurrent thymoma, but obtained good
outcome after aggressive treatment.Case presentation
Case 1
A 25-year-old, right-handed, Caucasian woman noticed
the inability to perform certain yoga positions with fatig-
ability and decreased stamina for exercise beginning at
the age of 22. She soon developed diplopia, facial and
proximal muscle weakness with difficulty lifting her arms
above her head and difficulty climbing stairs. She was
admitted to a community hospital and had an extensive
workup, including brain and spine images as well as
serum autoimmune studies, which were normal. She was
given one cycle of intravenous immunoglobulin (IVIG),
which slightly improved her symptoms.
Her condition deteriorated with difficulty chewing,
swallowing, and increasing weakness. She was referred
to us and manifested classical significant myasthenic
weakness in her extraocular, bulbar and proximal arm
and leg muscles. Repetitive nerve stimulation studies
revealed 17 percent compound muscle action potential
(CMAP) amplitude decrement in the right median nerve
and 19 percent in the left spinal accessory nerve. Forced
vital capacity was 1.65 liters. Her AChR binding anti-
body was elevated at 133.06 and blocking antibody was
positive at 43. She was classified as MGFA class IVb.
Prednisone, IVIG, and pyridostigmine were initiated.
A chest computed tomography (CT) scan showed a
large anterior mediastinal heterogeneous mass with solid
and cystic components measuring 6cm × 4.6cm × 5.2cm
with invasion of the pericardium. Video-assisted thora-
coscopy (VATS) and anterior mediastinoscopy were
performed. An extensive lesion was noted with local
adherence to the pulmonary left upper lobe and pres-
ence of a left pleural effusion. The invasive thymoma
was classified as Masaoka stage III.She received neoadjuvant chemotherapy consisting of
cisplatin and etoposide with 45Gy of radiation for tumor
reduction. She had a complicated clinical course with
numerous myasthenia crises requiring repeated intensive
care admission and endotracheal intubation for ventila-
tor support. Plasmapheresis and IVIG were administered
at different times. She later underwent a median sternot-
omy for a radical thymectomy with en bloc resection of
a portion of the left upper lobe of the lung. The final
pathology showed WHO type B1 with less than 10 per-
cent residual viable tumor. Five months after the initial
tumor was biopsied, she was found to have recurrent
focus of tumor on the left inferior phrenic nerve margin
requiring adjuvant radiation for another six weeks.
Serial chest imaging showed no evidence of recurrent
tumor. She is currently two years post thymectomy and
has significantly improved to an MGFA minimal mani-
festation status (MMS). She is currently maintained on a
low dose of both prednisone and pyridostigmine without
IVIG.Case 2
A 25-year-old, right-handed, Asian man started to notice
difficulty in chewing and weakness in both arms and
legs at age 20. He was given prednisone at a community
hospital but his symptoms did not improve. When he
was referred to us one month later, he had quickly pro-
gressed to an inability to ambulate, dysphagia, slurred
speech, severe ptosis, weakness chewing and diplopia.
His AChR-binding antibody was positive at 30.38 and
blocking antibody was elevated at 36. Forced vital cap-
acity was 1.3 liters. He was given IVIG, but no definite
improvement was noted. He was admitted to the inten-
sive care unit in myasthenia crisis and given aggressive
plasmapheresis and immunotherapy. He was classified
as generalized myasthenia gravis MGFA class IVb.
A CT scan of his chest revealed a 7.6cm × 6.1cm anter-
ior mediastinal mass with local invasion as well as some
pleural nodules, the largest of which was 2.4cm × 1.1cm.
A biopsy was done through VATS and his invasive thym-
oma was classified as Masaoka stage IVa with pleura dis-
semination. He was started on neoadjuvant chemotherapy
consisting of cisplatin and etoposide with radiation.
A turbulent clinical course ensued requiring repeated
plasmapheresis and IVIG. Our patient then improved.
His repeat chest image showed significant decrease in
the size of the anterior mediastinal mass and resolution
of the posterior pleural thickening five months later. He
was taken to the operating room (OR) and underwent
median sternotomy with resection of the anterior medias-
tinal mass, total radical thymectomy and resection of the
innominate vein successfully. Radiation therapy continued
postoperatively. The final pathology showed WHO type
Beydoun et al. Journal of Medical Case Reports 2014, 8:340 Page 3 of 5
http://www.jmedicalcasereports.com/content/8/1/340AB thymoma with invasion to the pleura and blood vessel
wall of the innominate vein.
Fluctuation and a difficult course followed requiring a
combined therapy including prednisone, pyridostigmine,
IVIG and azathioprine. He slowly improved to MGFA
class IIa and his prednisone and IVIG were gradually
reduced four months after the operation.
Serial chest imaging was performed and a pulmonary
cryptococcal nodule was detected two years following
the initial diagnosis of MG, which prompted fluconazole
treatment. Three years after the diagnosis, he reached
MGFA MMS and was maintained on low-dose prednisone
and azathioprine.
Our patient’s MG relapsed again after two years with
slurred speech, ptosis, double vision, and extremity
weakness secondary to medication noncompliance. He
was restarted immediately on prednisone, azathioprine
and IVIG; chest imaging showed increased size of a left
posteromedial pleural nodule to 2.7cm × 0.9cm. A biopsy
showed recurrent metastatic thymoma.
Chemotherapy with cisplatin, cytoxan, and doxorubicin
was begun. He underwent recurrent thymoma resection
five months later with left posterolateral thoracotomy with
excision of two pleural masses and excision of the old
lesions of the diaphragm with primary repair. The final
pathology showed metastatic thymoma in the left pleura
and diaphragm. He improved gradually after thoracotomy.
He is currently MGFA Class IIa and remains on combin-
ation therapy of prednisone, azathioprine and IVIG.
Discussion
Several retrospective studies have been conducted to
identify variables that influence the natural history of T-
MG and therapeutic approaches. Maggi et al. reviewed
197 patients with T-MG, with mean age at onset being
approximately 47 years. Twelve percent of the patients
had invasive thymoma in Masaoka stage III, 3 percent in
stage IVa and 0.5 percent in stage IVb. Mean age at
thymectomy was about 48 years. Almost 10 percent of
the patients had recurrent thymoma, which was 17 percent
with invasive thymoma stage III [11].
The study identified that early onset age before 45 as
well as invasive thymoma were significantly associated
with the persistence of symptoms. Invasive thymoma
was correlated with a higher probability of recurrence.
The chance of achieving remission in T-MG was 9.64
percent, but of those the majority were noninvasive stage
I thymoma [11].
Other studies looked into the prognostic factors for T-
MG and revealed that WHO classification had limitations
in accurately predicting the prognosis of the disease [6].
Although a study led by Ruffini et al. demonstrated that
WHO histologic classification and Masaoka stage are
interrelated in T-MG, in multivariate analysis only Masaokastage was an independent prognostic factor [12]. Further-
more, histological features had a lesser role in foreseeing
outcome after resection, thus Masaoka stage is believed to
be a better predictor of clinical behavior, recurrence, and
long-term survival.
One study found the rate of complete resectability
varied by stage; essentially 100 percent resectability for
stage II, 50 percent to 60 percent for stage III, and
approaching 0 percent for stage IVa tumors [13]. Only
completeness of resection was significantly correlated
with a better prognosis [14].
Another study demonstrated that survival rate was
significantly different among stage I, stage III, and stage IVa
with a significant correlation between complete resection
and survival. Significant correlation was found between no
invasion to the great vessel, invasion except for the great
vessel, and invasion to the great vessel [15].
Invasiveness remains the best predictor of relapse-free
survival after resection. Drop metastasis into ipsilateral
pleura and pericardium is a characteristic finding in inva-
sive thymoma. The metastases are frequently confined to
the pleura, pericardium, or diaphragm [6].
Lucchi et al. reviewed 123 patients diagnosed with T-MG
with a mean age of 56 years who underwent thymectomy
and revealed that higher complete MG remission rate was
achieved in early-stage thymoma. This is the first study
documenting that T-MG patients who achieved a complete
remission in MG had a significantly better prognosis.
Overall survival was dependent on the Masaoka stage, the
WHO classification, and the achievement of complete
remission of myasthenia symptoms [16].
Compared to the above statistical data of incidence,
survival rate, prognostic factors and, recurrent frequency
of the T-MG, the two cases of MG associated with inva-
sive thymoma we report here are rare.
Our patients’ symptoms of MG occurred at very young
age, 20 and 22 years old respectively, whereas studies
showed the mean age of onset was 47 to 56 with a peak
at 50 years. Among 197 patients in the Maggi et al.
study, only 10 patients were in the age group 20 to 29
years with low-stage invasive thymoma, and none of
them were above stage III. Of patients of all ages with
WHO type B, only two had Masaoka stage III. None of
the patients with WHO type AB had Masaoka stage IV.
The incidence of young patients with MG associated
with high-stage invasive thymoma is extremity sporadic,
which highlights the continued challenge in managing
MG associated with malignant thymoma and the necessity
of multi-specialist involvement.
Although radial surgical resection is the cornerstone of
therapy in T-MG, possibility of completeness of resection
is very low in high-stage invasive thymoma and almost
impossible for stage IVa tumors [17]. The consensus is
that patients with invasive thymoma, especially stage III
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therapy, however, to date, no standard therapeutic strategy
has been validated.
Unfortunately, the recurrence of invasive thymoma is
a frequent event. When the thymoma invades the pleura
or the pericardium, radical excision is nearly impossible.
Studies have identified that young onset age, high-stage
invasive thymoma, recurrence rate and inability to achieve
complete remission in MG lead to poor prognosis for
T-MG patients. Both of our patients, however, had favor-
able outcomes despite those factors. The reasons for our
success are multifactorial including:
1. Early and accurate diagnosis to safeguard the
myasthenia crisis.
2. Plasmapheresis and IVIG infusion prior to surgery
to remove a great deal of the circulating surviving
pathogenic antibodies.
3. Aggressive neoadjuvant chemotherapy and
radiotherapy to shrink the tumor size to ensure a
complete surgical resection and continuation of
radiation post operation for any further invasion.
4. Adequate long-term combined immunosuppression
and immunomodulation treatment to achieve
control of the clinical symptoms.
5. Regular image surveillance to detect any recurrent
tumor in the early stage.
Most importantly, thymomatous MG is a distinct disease,
and the collaboration among thoracic surgeon, oncologist,
radiologist and neurologist to monitor the neurological
and oncological symptoms optimizes treatment through a
synergistic effect and provides a favorable outcome to the
patients.
Conclusions
There is a known and established relationship between
thymoma and myasthenia gravis. Although thymomatous
myasthenia gravis tends to have a difficult clinical course
and poor prognosis, early and aggressive treatment along
with multidisciplinary management may improve the out-
come of these patients.
Consent
Written informed consent was obtained from both patients
for publication of this case report and any accompanying
images. A copy of the written consent is available for review
by the Editor-in-Chief of this journal.
Competing interests
The authors declare that they have no competing interests.
Authors’ contributions
HG, NA and SRB were both involved in clinical diagnostic evaluation and
management. HG, NA and SRB performed the electrodiagnostic studies. HG
and NA generated the first draft of the manuscript. SRB and RAR reviewedthe manuscript. RAR revised and edited the manuscript using an additional
literature search. SRB and RAR were responsible for the intellectual content
of the manuscript. All authors participated in and provided significant
contributions in writing the manuscript. All authors read and approved the
final manuscript.
Authors’ information
HG is a neurophysiology fellow at the University of Southern California-Keck
School of Medicine-Los Angeles County Medical Center. NA is a staff neurologist
at Kaiser Permanente. SRB is a professor of neurology at the University of Southern
California-Keck School of Medicine-Los Angeles County Medical Center. SRB is
Director of the University of Southern California Neuromuscular Program, a
Fellow of the American Academy of Neurology and the American Association
of Neuromuscular and Electrodiagnostic Medicine, and is board certified by
the American Board of Psychiatry and Neurology in Neurology, Clinical
Neurophysiology, Pain Medicine, and Neuromuscular Medicine. SRB is also
board certified by the American Board of Electrodiagnostic Medicine in
Electrodiagnostic Medicine. SRB is a member of the advisory board and the
scientific committee of the Myasthenia Gravis Foundation of California. RAR
is a Deputy Editor for the Journal of Medical Case Reports, an Associate
Neurology Editor for BMC Neurology, Grand Rounds and WebmedCentral, and
a Section Editor for BMC Research Notes. RAR practices general neurology at
Neurology Consultants Medical Group, serves as Medical Director of the PIH
Health Stroke Program, is a Clinical Assistant Professor of Neurology at the
University of Southern California-Keck School of Medicine-Los Angeles County
Medical Center, and is a Fellow of the American Association of Neuromuscular
and Electrodiagnostic Medicine. RAR is board certified by the American
Board of Psychiatry and Neurology in Neurology and Vascular Neurology, and
Neurocritical Care and Neuroimaging by the United Council of Neurologic
Subspecialties. RAR is also board certified by the American Board of
Electrodiagnostic Medicine in Electrodiagnostic Medicine. RAR is a former
president of the Los Angeles Neurological Society and a current Fellow of
the American Academy of Neurology.
Acknowledgments
We gratefully acknowledge both patients for allowing us to publish their
case reports.
Author details
1Department of Neurology, University of Southern California, Keck School of
Medicine, Los Angeles County Medical Center, 1520 San Pablo Street, Los
Angeles, CA 90033, USA. 2Department of Neurology, Kaiser Permanente,
15788 Midwood Drive, Granada Hills, CA 91344, USA. 3Department of
Neurology, PIH Health Stroke Program, 12401 Washington Boulevard,
Whittier, CA 90602, USA.
Received: 19 May 2014 Accepted: 20 August 2014
Published: 13 October 2014
References
1. Tormoehlen LM, Pascuzzi RM: Thymoma, myasthenia gravis, and other
paraneoplastic syndromes. Hematol Oncol Clin North Am 2008, 22:509–526.
2. Cheney RT: The biologic spectrum of thymic epithelial neoplasms:
current status and future prospects. J Natl Compr Canc Netw 2010,
8:1322–1328.
3. Romi F: Thymoma in myasthenia gravis: from diagnosis to treatment.
Autoimmune Dis 2011, 2011:474512.
4. Okumura M, Shiono H, Minami M, Inoue M, Utsumi T, Kadota Y, Sawa Y:
Clinical and pathological aspects of thymic epithelial tumors. Gen Thorac
Cardiovasc Surg 2008, 56:10–16.
5. Amdahl C, Alseth EH, Gilhus NE, Nakkestad HL, Skeie GO: Polygenic disease
associations in thymomatous myasthenia gravis. Arch Neurol 2007,
64:1729–1733.
6. Mikhail M, Mekhail Y, Mekhail T: Thymic neoplasms: a clinical update.
Curr Oncol Rep 2012, 14:350–358.
7. Rosai J, Sobin LH: Histological typing of tumors of the thymus. In World
Health Organization International Histological Classification of Tumours. 2nd
edition. New York: Springer; 1999:9–14.
8. Masaoka A, Monden Y, Nakahara K, Tanioka T: Follow-up study of
thymomas with special reference to their clinical stages. Cancer 1981,
48:2485–2492.
Beydoun et al. Journal of Medical Case Reports 2014, 8:340 Page 5 of 5
http://www.jmedicalcasereports.com/content/8/1/3409. Jaretzki A 3rd, Barohn RJ, Ernstoff RM, Kaminski HJ, Keesey JC, Penn AS,
Sanders DB: Myasthenia gravis: recommendations for clinical research
standards. Task Force of the Medical Scientific Advisory Board of the
Myasthenia Gravis Foundation of America. Neurology 2000, 55:16–23.
10. Maggi G, Casadio C, Cavallo A, Cianci R, Molinatti M, Ruffini E: Thymectomy
in myasthenia gravis. Results of 662 cases operated upon in 15 years.
Eur J Cardiothorac Surg 1989, 3:504–509. discussion 510-511.
11. Maggi L, Andreetta F, Antozzi C, Baggi F, Bernasconi P, Cavalcante P,
Cornelio F, Muscolino G, Novellino L, Mantegazza R: Thymoma-associated
myasthenia gravis: outcome, clinical and pathological correlations in 197
patients on a 20-year experience. J Neuroimmunol 2008, 201–202:237–244.
12. Ruffini E, Filosso PL, Mossetti C, Bruna MC, Novero D, Lista P, Casadio C,
Oliaro A: Thymoma: inter-relationships among World Health Organization
histology, Masaoka staging and myasthenia gravis and their independent
prognostic significance: a single-centre experience. Eur J Cardiothorac Surg
2011, 40:146–153.
13. Thomas CR, Wright CD, Loehrer PJ: Thymoma: state of the art. J Clin Oncol
1999, 17:2280–2289.
14. Margaritora S, Cesario A, Cusumano G, Meacci E, D'Angelillo R, Bonassi S,
Carnassale G, Porziella V, Tessitore A, Vita ML, Lauriola L, Evoli A, Granone P:
Thirty-five-year follow-up analysis of clinical and pathologic outcomes of
thymoma surgery. Ann Thorac Surg 2010, 89:245–252. discussion 252.
15. Matsushima S, Yamamoto H, Egami K, Suzuki S, Tanaka S: Evaluation of the
prognostic factors after thymoma resection. Int Surg 2001, 86:103–106.
16. Lucchi M, Ricciardi R, Melfi F, Duranti L, Basolo F, Palmiero G, Murri L, Mussi
A: Association of thymoma and myasthenia gravis: oncological and
neurological results of the surgical treatment. Eur J Cardiothorac Surg
2009, 35:812–816. discussion 816.
17. Lococo F, Cesario A, Margaritora S, Granone P: Twenty-one-year survival in
an invasive thymoma successfully treated with seven-fold iterative
surgery. Interact Cardiovasc Thorac Surg 2010, 11:322–324.
doi:10.1186/1752-1947-8-340
Cite this article as: Beydoun et al.: Myasthenia gravis associated with
invasive malignant thymoma: two case reports and a review of the
literature. Journal of Medical Case Reports 2014 8:340.Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
